A Trial of Novaferon in Asymptomatic or Mild COVID-19 Patients
Status:
Not yet recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
This is a phase III randomized, double blinded, placebo-controlled multi-center study to
assess the efficacy and safety of aerosolized Novaferon for the treatment of asymptomatic or
mildly patients infected with SARS-CoV-2.